Helixgate

Helixgate

Uncategorized

Monoclonal Antibodies: Unlocking Cost and Efficiency Gains in Downstream Processing

Published

on



Image of Kristina Pleitt

Kristina Pleitt

Senior Staff Scientist
Thermo Fisher Scientific

Panelist

Image of Kristina Pleitt

Kristina Pleitt

Kristina Pleitt is a senior staff scientist at Thermo Fisher Scientific with 15 years of experience in biopharmaceutical process development and manufacturing. Her expertise includes downstream process development, process scale-up, integrated continuous processing, and clinical and commercial production, with a particular focus on advancing intensified downstream strategies that improve process efficiency, performance, and manufacturability.


Broadcast Date: 

  • Time: 

Analytical developers and downstream scientists are under constant pressure to improve process efficiency while maintaining product quality for monoclonal antibodies (mAbs). Yet, many platform purification processes still leave untapped opportunities for optimization, cost reduction, and simplification.

In this webinar, our speaker will explore a series of practical, chromatography-focused strategies designed to enhance mAb purification performance while reducing cost of goods (COGs). Using real-world examples and process scenarios, attendees will gain insight into:

  • Identifying opportunities to simplify traditional mAb purification workflows
  • Improving Protein A performance and lifetime to drive cost savings
  • Enabling efficient two-step downstream processes through better impurity management
  • Addressing difficult HCP and aggregate clearance challenges with advanced polishing strategies

A live Q&A session will follow the presentation, offering you a chance to engage directly with our expert and discuss how these approaches can be applied to your own processes.

Produced with support from:

Thermo Fisher logo

The post Monoclonal Antibodies: Unlocking Cost and Efficiency Gains in Downstream Processing appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

STAT+: More political interference at the FDA?

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

This is a photo of a young RFK Jr. trying to ride a small rhino. Send news tips and RINO jokes to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal.

Former DOGE co-founder v. former state Covid-19 czar

Although most people whom DOGE fired from HHS probably don’t live in Ohio, they may feel a personal connection to the gubernatorial race there.

Continue to STAT+ to read the full story…

Read More

Published

on

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

This is a photo of a young RFK Jr. trying to ride a small rhino. Send news tips and RINO jokes to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal.

Former DOGE co-founder v. former state Covid-19 czar

Although most people whom DOGE fired from HHS probably don’t live in Ohio, they may feel a personal connection to the gubernatorial race there.

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

Angelini inks $4.1B Catalyst buy to enter US rare disease market

Published

on

Catalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings.

Continue Reading

Uncategorized

Gilead wipes out most of Arcellx workforce

Published

on

Gilead is laying off Arcellx employees in California and Maryland, with some cuts effective this year and the remainder happening in 2027.

Continue Reading
Advertisement

Trending